Fortgeschrittenes Prostatakarzinom: Sequenz aus androgenrezeptorgerichteten Substanzen und Chemotherapie entscheidet über das Langzeitüberleben
Wuelfing C, Goebell P, Eichenauer R, Lange C, Machtens S, Schwentner C, Todenhoefer T, Tauber R, Schostak M (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 60
Pages Range: 212-221
Journal Issue: 2
DOI: 10.1007/s00120-020-01411-6
Abstract
The treatment of advanced prostate cancer is changing. New study data and the resulting new therapeutic options have led to increasingly differentiated treatment decisions. Despite the changing therapy landscape, taxane-based chemotherapy—being a life-prolonging treatment—remains an indispensable therapeutic component for chemotherapy-fit patients in the metastatic setting. The current results of the randomized study CARD show that cabazitaxel has a higher oncological effectiveness, including a significant survival benefit and no negative impact on quality of life parameters, compared to a second androgen receptor targeted agent (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after treatment with docetaxel and an androgen receptor-targeted agent (ARTA). In mCNPC the combination therapies of ADT (androgen deprivation therapy) plus docetaxel or of ADT plus ARTA have been established. In addition, three ARTAs tested in recent phase III studies in a clinical setting for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) showed that their use significantly prolongs metastasis-free survival and overall survival. The potential early use of ARTAs also has implications for the treatment of mCNPC. The aim of this publication is to provide guidance for clinical routine and to develop criteria for individual therapy decisions with a special focus on the use of chemotherapy.
Authors with CRIS profile
Involved external institutions
Marien-Krankenhaus Bergisch Gladbach
Germany (DE)
Klinikum Stuttgart
Germany (DE)
Universitätsklinikum Magdeburg A.ö.R.
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Asklepios Kliniken
Germany (DE)
Germany (DE)
Klinikum Stuttgart
Germany (DE)
Universitätsklinikum Magdeburg A.ö.R.
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Asklepios Kliniken
Germany (DE)
How to cite
APA:
Wuelfing, C., Goebell, P., Eichenauer, R., Lange, C., Machtens, S., Schwentner, C.,... Schostak, M. (2021). Fortgeschrittenes Prostatakarzinom: Sequenz aus androgenrezeptorgerichteten Substanzen und Chemotherapie entscheidet über das Langzeitüberleben. Urologe, 60(2), 212-221. https://doi.org/10.1007/s00120-020-01411-6
MLA:
Wuelfing, Christian, et al. "Fortgeschrittenes Prostatakarzinom: Sequenz aus androgenrezeptorgerichteten Substanzen und Chemotherapie entscheidet über das Langzeitüberleben." Urologe 60.2 (2021): 212-221.
BibTeX: Download